Clinical question: In poor-prognosis metastatic nonseminomatous germ-cell cancer, does intensified induction/sequential chemotherapy improve efficacy over standard BEP/EP?
Design: Joint randomized MRC/EORTC trial; 380 accrued, 371 eligible/assessable after exclusions. BEP/EP versus intensified BOP/VIP-B. Median follow-up 3.1 years, maximum 5.8 years.
Complete response with chemotherapy alone: 79/185 (57%) BEP/EP vs 72/186 (54%) BOP/VIP-B; P=.687.
1-year failure-free survival: 60% vs 53%. There was no significant difference in time to progression, failure-free survival or OS (P=.21, .101 and .190 respectively).
Toxic deaths: 9/≈190 (5%) with BEP/EP vs 18/≈190 (9%) with BOP/VIP-B. Absolute excess ≈4 percentage points; NNH ≈ 25 for treatment-related death.
Grade 3–4 myelosuppression, febrile neutropenia and weight loss were more pronounced with intensified therapy.
This was a randomized superiority comparison of intensified induction/sequential chemotherapy versus standard cisplatin-based therapy in poor-prognosis metastatic NSGCT. The study was designed to determine whether intensification could improve response and survival, not merely non-inferiority.
The intensified regimen failed to produce a meaningful efficacy advantage and caused substantially more severe toxicity, including approximately twice as many toxic deaths. This is an important negative trial: intensification is not justified simply because poor-prognosis disease is biologically aggressive. The standard BEP/EP strategy achieved at least comparable disease control with lower treatment-related mortality.
MRC/EORTC randomized trial, JCO
BOP/VIP-B is historical evidence for alternative chemotherapy approaches in germ-cell tumours, but BEP remains the standard regimen when bleomycin is safe and appropriate. Alternative regimens should be reserved for defined contraindications and specialist-centre decisions; prognosis group and marker kinetics determine cycle number and intensification.